PL2183263T3 - Sposoby i związki przydatne do otrzymywania inhibitorów kotransportera 2 sodowo-glukozowego - Google Patents
Sposoby i związki przydatne do otrzymywania inhibitorów kotransportera 2 sodowo-glukozowegoInfo
- Publication number
- PL2183263T3 PL2183263T3 PL08826634T PL08826634T PL2183263T3 PL 2183263 T3 PL2183263 T3 PL 2183263T3 PL 08826634 T PL08826634 T PL 08826634T PL 08826634 T PL08826634 T PL 08826634T PL 2183263 T3 PL2183263 T3 PL 2183263T3
- Authority
- PL
- Poland
- Prior art keywords
- transporter
- inhibitors
- preparation
- methods
- compounds useful
- Prior art date
Links
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95212207P | 2007-07-26 | 2007-07-26 | |
| EP08826634A EP2183263B1 (en) | 2007-07-26 | 2008-07-17 | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
| PCT/US2008/070250 WO2009014970A1 (en) | 2007-07-26 | 2008-07-17 | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2183263T3 true PL2183263T3 (pl) | 2012-03-30 |
Family
ID=39877996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08826634T PL2183263T3 (pl) | 2007-07-26 | 2008-07-17 | Sposoby i związki przydatne do otrzymywania inhibitorów kotransportera 2 sodowo-glukozowego |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8026347B2 (pl) |
| EP (1) | EP2183263B1 (pl) |
| JP (2) | JP5653213B2 (pl) |
| KR (1) | KR101663324B1 (pl) |
| CN (1) | CN101801989B (pl) |
| AR (2) | AR067701A1 (pl) |
| AT (1) | ATE530558T1 (pl) |
| AU (1) | AU2008279424B2 (pl) |
| CA (1) | CA2694029C (pl) |
| CL (1) | CL2008002169A1 (pl) |
| CO (1) | CO6260141A2 (pl) |
| DK (1) | DK2183263T3 (pl) |
| EA (1) | EA017411B1 (pl) |
| EC (1) | ECSP109987A (pl) |
| ES (1) | ES2375800T3 (pl) |
| IL (1) | IL203209A (pl) |
| NZ (1) | NZ582536A (pl) |
| PL (1) | PL2183263T3 (pl) |
| PT (1) | PT2183263E (pl) |
| TW (2) | TWI419886B (pl) |
| UA (1) | UA107175C2 (pl) |
| WO (1) | WO2009014970A1 (pl) |
| ZA (1) | ZA201000219B (pl) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI499414B (zh) * | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| WO2010009243A1 (en) | 2008-07-15 | 2010-01-21 | Theracos, Inc. | Deuterated benzylbenzene derivatives and methods of use |
| TWI472521B (zh) * | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法 |
| ES2380408T3 (es) | 2008-08-28 | 2012-05-11 | Pfizer Inc. | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
| US8669380B2 (en) | 2009-11-02 | 2014-03-11 | Pfizer Inc. | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| CN102711739B (zh) | 2009-11-13 | 2015-12-16 | 阿斯利康(瑞典)有限公司 | 双层片剂 |
| BR112012011274A2 (pt) | 2009-11-13 | 2016-04-12 | Astrazeneca Uk Ltd | formulação de metformina de massa reduzida e sua combinação |
| CA3002948C (en) | 2009-11-13 | 2020-10-27 | Astrazeneca Uk Limited | Immediate release tablet formulations |
| TWI562775B (en) * | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
| WO2011153712A1 (en) * | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| CN103370064A (zh) | 2010-09-03 | 2013-10-23 | 百时美施贵宝公司 | 使用水溶性抗氧化剂的药物制剂 |
| AU2012212448B9 (en) | 2011-02-01 | 2015-06-25 | Astrazeneca Uk Limited | Pharmaceutical formulations including an amine compound |
| JP5876570B2 (ja) | 2011-06-01 | 2016-03-02 | グリーン・クロス・コーポレイションＧｒｅｅｎ Ｃｒｏｓｓ Ｃｏｒｐ． | Ｓｇｌｔ２阻害剤としての新規のジフェニルメタン誘導体 |
| WO2012163990A1 (en) | 2011-06-03 | 2012-12-06 | Boehringer Ingelheim International Gmbh | Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents |
| WO2013152476A1 (en) | 2012-04-10 | 2013-10-17 | Theracos, Inc. | Process for the preparation of benzylbenzene sglt2 inhibitors |
| TR201908247T4 (tr) * | 2012-11-20 | 2019-06-21 | Lexicon Pharmaceuticals Inc | Sodyum glikoz birlikte taşıyıcı 1 inhibitörleri. |
| ES2959444T3 (es) | 2013-04-04 | 2024-02-26 | Boehringer Ingelheim Vetmedica Gmbh | Tratamiento de trastornos metabólicos en animales equinos |
| EP2895490B1 (en) | 2013-09-27 | 2016-10-19 | Sunshine Lake Pharma Co., Ltd. | Glucopyranosyl derivatives and their uses in medicine |
| WO2015051484A1 (en) | 2013-10-12 | 2015-04-16 | Theracos, Inc. | Preparation of hydroxy-benzylbenzene derivatives |
| EP3082829B1 (en) | 2013-12-17 | 2021-02-17 | Boehringer Ingelheim Vetmedica GmbH | Sglt2 inhibitors for the treatment of metabolic disorders in feline animals |
| EA032558B1 (ru) | 2014-01-23 | 2019-06-28 | Бёрингер Ингельхайм Ветмедика Гмбх | Лечение метаболических расстройств у представителей собачьих |
| DK3721882T3 (da) | 2014-04-01 | 2024-10-21 | Boehringer Ingelheim Vetmedica Gmbh | Behandling af hypofyse pars intermedia-dysfunktion hos hestedyr |
| KR102539788B1 (ko) | 2014-09-25 | 2023-06-07 | 베링거잉겔하임베트메디카게엠베하 | 말과 동물의 대사 장애를 예방하기 위한 sglt2 억제제와 도파민 작용제의 병용 치료 |
| JP6727419B2 (ja) * | 2016-05-25 | 2020-07-22 | クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド | ナトリウム−グルコース共輸送体阻害薬の新規な結晶形及びその製造方法並びに用途 |
| KR102226465B1 (ko) * | 2016-05-28 | 2021-03-11 | 하이난 수안주 파마 코포레이션 리미티드 | 나트륨-글루코스 공수송체 2에 대한 억제제의 결정형 |
| MY203941A (en) | 2016-06-17 | 2024-07-25 | Daewoong Pharmaceutical Co Ltd | Method for producing diphenylmethane derivative |
| CA3041169A1 (en) | 2016-10-19 | 2018-04-26 | Boehringer Ingelheim International Gmbh | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
| CN107540685B (zh) * | 2017-09-04 | 2020-05-05 | 杭州科巢生物科技有限公司 | 一种Sotagliflozin的制备方法及其中间体 |
| US20210113561A1 (en) | 2018-04-17 | 2021-04-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN108675976B (zh) * | 2018-05-14 | 2020-07-14 | 浙江宏元药业股份有限公司 | 一种6-卤代葡萄糖碳苷及其制备方法和应用 |
| BR112021002523A2 (pt) | 2018-08-13 | 2021-05-04 | Daewoong Pharmaceutical Co., Ltd. | método para preparar um composto |
| CN110818722B (zh) * | 2018-08-14 | 2022-12-02 | 苏州鹏旭医药科技有限公司 | 三种化合物及其制备方法和在合成索格列净中的用途 |
| JP7425793B2 (ja) | 2018-10-29 | 2024-01-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用 |
| CA3112510A1 (en) | 2018-10-29 | 2020-05-07 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| EP3771480A1 (en) * | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Continuous process for preparing the crystalline form ii of sotagliflozin |
| BR112022010385A2 (pt) | 2019-11-28 | 2022-08-23 | Boehringer Ingelheim Vetmedica Gmbh | Uso de inibidores de sglt-2 na secagem de mamíferos não humanos |
| KR20220143732A (ko) | 2020-02-17 | 2022-10-25 | 베링거잉겔하임베트메디카게엠베하 | 고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용 |
| EP4376830A1 (en) | 2021-07-28 | 2024-06-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals |
| WO2023006745A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
| US20240398845A1 (en) | 2021-07-28 | 2024-12-05 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines |
| CN113880701A (zh) * | 2021-10-10 | 2022-01-04 | 浙江司太立制药股份有限公司 | 一种抗糖尿病药物中间体及其制备方法 |
| JP2025516857A (ja) | 2022-05-25 | 2025-05-30 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | Ｓｇｌｔ－２阻害薬を含む水性医薬組成物 |
| US20240307628A1 (en) | 2023-03-06 | 2024-09-19 | Boehringer Ingelheim Vetmedica Gmbh | Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s) |
| AU2024276892A1 (en) | 2023-05-24 | 2025-10-16 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan |
| CN121175053A (zh) | 2023-05-24 | 2025-12-19 | 勃林格殷格翰动物保健有限公司 | 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防 |
| WO2025160910A1 (en) * | 2024-02-01 | 2025-08-07 | New Wish Biotechnology Wuxi Co., Ltd. | Indazole compound and pharmaceutical composition, preparation method and use thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753789A (en) * | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| ES2254376T3 (es) | 2000-03-17 | 2006-06-16 | Kissei Pharmaceutical Co., Ltd. | Derivados glucopiranosiloxibencilbenceno, preparaciones medicinales que los contienen e intermediarios para la preparacion de los indicados derivados. |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| US6555519B2 (en) | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
| WO2002044192A1 (en) | 2000-11-30 | 2002-06-06 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| DK1385856T3 (da) * | 2001-04-11 | 2006-05-15 | Bristol Myers Squibb Co | Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder |
| US6562791B1 (en) | 2002-03-29 | 2003-05-13 | Council Of Scientific And Industrial Research | Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof |
| WO2003087119A1 (en) * | 2002-04-12 | 2003-10-23 | Achillion Pharmaceuticals, Inc. | METHOD FOR SYNTHESIZING β-L-FLUORO-2´,3´DIDEHYDROCYTIDINE (β-L-FD4C) |
| MXPA05000725A (es) | 2002-08-09 | 2005-04-08 | Taisho Pharma Co Ltd | Procedimiento para la produccion selectiva de aril-5-tio-??-d-aldohexopiranosidos. |
| PL378324A1 (pl) | 2003-01-03 | 2006-03-20 | Bristol-Myers Squibb Company | Sposób wytwarzania C-aryloglukozydowych inhibitorów SGLT2 |
| US7368475B2 (en) * | 2003-03-12 | 2008-05-06 | Kemin Pharma Bvba | Furanose-type bicyclic carbohydrates with biological activity |
| ATE510834T1 (de) | 2003-03-14 | 2011-06-15 | Astellas Pharma Inc | C-glykosid-derivate zur behandlung von diabetes |
| WO2006018150A1 (de) * | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| JP5264183B2 (ja) | 2005-02-23 | 2013-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル置換（（ヘテロ）アリールエチニル−ベンジル）−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体２（ｓｇｌｔ２）インヒビターとしてのそれらの使用 |
| TWI499414B (zh) * | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| WO2008044268A1 (en) * | 2006-10-05 | 2008-04-17 | Panasonic Corporation | Transmitter apparatus and transmitting method |
| US7846945B2 (en) * | 2007-03-08 | 2010-12-07 | Lexicon Pharmaceuticals, Inc. | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use |
| TWI472521B (zh) | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法 |
-
2008
- 2008-07-17 UA UAA201002095A patent/UA107175C2/ru unknown
- 2008-07-17 KR KR1020107001659A patent/KR101663324B1/ko active Active
- 2008-07-17 NZ NZ582536A patent/NZ582536A/en unknown
- 2008-07-17 ES ES08826634T patent/ES2375800T3/es active Active
- 2008-07-17 CA CA2694029A patent/CA2694029C/en active Active
- 2008-07-17 WO PCT/US2008/070250 patent/WO2009014970A1/en not_active Ceased
- 2008-07-17 CN CN200880100489.2A patent/CN101801989B/zh active Active
- 2008-07-17 EP EP08826634A patent/EP2183263B1/en active Active
- 2008-07-17 US US12/174,722 patent/US8026347B2/en active Active
- 2008-07-17 AU AU2008279424A patent/AU2008279424B2/en active Active
- 2008-07-17 EA EA201070186A patent/EA017411B1/ru not_active IP Right Cessation
- 2008-07-17 JP JP2010518296A patent/JP5653213B2/ja active Active
- 2008-07-17 AT AT08826634T patent/ATE530558T1/de active
- 2008-07-17 DK DK08826634.1T patent/DK2183263T3/da active
- 2008-07-17 PL PL08826634T patent/PL2183263T3/pl unknown
- 2008-07-17 PT PT08826634T patent/PT2183263E/pt unknown
- 2008-07-21 TW TW097127665A patent/TWI419886B/zh active
- 2008-07-21 TW TW102129521A patent/TWI506024B/zh active
- 2008-07-24 CL CL2008002169A patent/CL2008002169A1/es unknown
- 2008-07-25 AR ARP080103246A patent/AR067701A1/es active IP Right Grant
-
2010
- 2010-01-10 IL IL203209A patent/IL203209A/en active IP Right Grant
- 2010-01-12 ZA ZA2010/00219A patent/ZA201000219B/en unknown
- 2010-02-23 EC EC2010009987A patent/ECSP109987A/es unknown
- 2010-02-25 CO CO10022864A patent/CO6260141A2/es not_active Application Discontinuation
-
2011
- 2011-08-11 US US13/207,576 patent/US8293878B2/en active Active
-
2013
- 2013-08-28 JP JP2013176646A patent/JP5764174B2/ja active Active
-
2018
- 2018-08-03 AR ARP180102213 patent/AR112669A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201000219B (en) | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors | |
| HUS1900038I1 (hu) | Nátrium-glükóz kotranszporter-2 inhibitorai és alkalmazási eljárásaik | |
| IL190135A0 (en) | Process for the preparation of pyrimidinedione derivatives | |
| IL198847A (en) | Process for making 2-imino-thiazolidine-4-on and several such histories | |
| IL190137A0 (en) | Crystals of laquinimod sodium, and process for the manufacture thereof | |
| ZA200903533B (en) | Process for the preparation of rosuvastatin | |
| EP1938842A4 (en) | METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS | |
| ZA200710914B (en) | Process for the preparation of sulfonamide derivatives | |
| GB0910201D0 (en) | The preparation method of 2-deoxy-l-ribose | |
| EP1893625A4 (en) | PROCESS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | |
| IL200087A0 (en) | Novel crystal of piperacillin sodium | |
| PT2170920E (pt) | Sais estáveis de s-adenosilmetionina e processo para a sua preparação. | |
| EP1883619A4 (en) | PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRAFLUOROBENZYLANILINE COMPOUND AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | |
| IL198848A0 (en) | Sodium salt of disaccharide compound, method for producing the same, and use of the same | |
| EP1964538A4 (en) | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL SUBSTANCES | |
| EP1984327A4 (en) | IMPROVED METHOD FOR THE PRODUCTION OF CILASTATIN AND ITS SODIUM SALT | |
| IL183378A0 (en) | Methods of making pravastatin sodium | |
| AU2007322712B2 (en) | Sodium salt of disaccharide compound, method for producing the same, and use of the same | |
| ITMI20060489A1 (it) | Procedimento per la preparazione di 1-beono-3-trifluorometossibenzene | |
| ITMI20052464A1 (it) | Procedimento per la preparazi9one di norelgestromin norelgestromina | |
| ZA200706203B (en) | Processes and compounds for the preparation of substituted naphthylindole derivatives | |
| ITMI20062504A1 (it) | Procedimento per la preparazione di 17alfa-cianometil-17beta-idrossi steroidi | |
| HK1128248A (en) | Use of glycolipids as adjuvants | |
| GB0620693D0 (en) | Composition and methods for the treatment of degenerative disease | |
| ITMI20061096A1 (it) | Procedimento per la preparazione di (1-tia-)3-cefem derivati |